Head and neck squamous cell carcinoma
Conditions
Interventions
Sub-mucosal or subcutaneous administrations of 111In-labeled alpha-GalactosylCeramide pulsed DCs are performed on day 7 after the entry.
Sponsors
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Performance status 0-1; Normal bone marrow, liver and renal functions; NKT cells are detected at least 10 cells in 1 mL of peripheral blood.
Exclusion criteria
Exclusion criteria: Infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; serious cardiac disease; recieived concurrent corticosteroid therapy; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to participate in this study by principle investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The migration of the radioactive 111In-labeled DCs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The immunological responses. | — |
Countries
Japan
Contacts
Public ContactShigetoshi Horiguchi
Graduate School of Medicine, Chiba University Department of Otorhinolaryngology, Head and Neck Surgery
Outcome results
None listed